Page 2434 - Williams Hematology ( PDFDrive )

2405
2404 Index Index 2405

B-cell progenitors, 270 BCL11A, 736 history, 1611
B-cell prolymphocytic lymphoma, 1542 Bcl11b, 1156 in HIV-associated disease, 1248
B-cell receptors (BCRs), 1151, 1528–1529 BCL11B, 166 with radiation therapy, 1613
B cells. See also Lymphocytes Bcl-W, 206 in unfavorable limited-stage disease, 1613
in chronic inflammation, 291 BCL-X, 210 BEAM regimen
development, 61, 1151, 1155, 1589–1590, Bcl-X , 206, 483 for diffuse large B-cell lymphoma, 1632
L
1589f, 1707–1708 BCL-XL, 1172 for Hodgkin lymphoma, 1616
differentiation, 1169, 1172 BCMA (B-cell maturation antigen), 1606 Becaplermin, 1848
disorders, 1195, 1196t, 1215 BCNU (bischloroethylnitrosourea). See Beclin, 206
fetal, 101, 1151 Carmustine (BCNU) Bee stings, 809, 970
function, in neonate, 108–109 BCR, 176, 1441–1442, 1442f, 1666, 1710 Behçet disease, 2103
immunoglobulins and activation of, 1163 BCR-ABL1 Belching, history of, 5
in lymph nodes, 93 in acute lymphoblastic leukemia, 183, 221t, Belinostat, 1696, 1696t
memory, 1172 1508, 1513t, 1521, 1521t Bence Jones proteinuria, 1721, 1725, 1810
monocytoid, 1595 in acute myelogenous leukemia, 1384t Bendamustine
neoplasms. See B-cell neoplasms apoptosis and, 1444 adverse effects, 1534
persistent polyclonal lymphocytosis, cell adhesion and, 1440–1441 for chronic lymphocytic leukemia, 1534,
1200–1202, 1201f in chronic myelogenous leukemia 1537
receptor diversity, 1177 apoptosis and, 1444 for follicular lymphoma, 1644, 1645t, 1647,
in spleen, 90, 90f cell adhesion and, 1440–1441 1649
BCL2 (BCL-2) CML stem cell formation and, 1439 for mantle cell lymphoma, 1656, 1659t
in apoptosis, 209–210 detection, 176f for myeloma, 1755
in chronic lymphocytic leukemia, 1529 disease progression and, 1464–1465 pharmacology, 330
in diffuse large B-cell lymphoma, 187, in healthy subjects, 1443 Benign monoclonal gammopathy. See
1596, 1626, 1627t, 1632 imatinib resistance and, 178, 230t, 1439 Essential monoclonal gammopathy
in “double-hit” lymphoma, 1674 inhibition of, 176 Benzene exposure
in follicular lymphoma, 187, 236t, 1576, molecular pathology, 1441–1442, 1441f, acute myelogenous leukemia and, 1319, 1374
1576f, 1594, 1642 1442f aplastic anemia and, 516–517
in memory B cells, 1172 progenitors, 1440 myelodysplastic syndromes and, 1342,
in Waldenström macroglobulinemia, 1785 prognosis and, 221t, 230t 1345
BCL2A1, 414 signal transduction and, 1443–1444, primary myelofibrosis and, 1319
Bcl-2 family, 205–206 1444f Benzocaine, toxic methemoglobinemia and,
in apoptosis, 206, 208–209, 208f, 237 in clonal myeloid disorders, 1278 789
in caspase activation, 204t detection, 1447–1448 Berger disease, 1161
in chronic lymphocytic leukemia, 1528, in healthy subjects, 1443 Bernard-Soulier syndrome (glycoprotein
1539 molecular pathology, 1441–1442, 1442f Ib-IX-V defect), 2048–2050
in diffuse large B-cell lymphoma, 198 p210 BCR-ABL fusion protein, 1442–1443 clinical features, 2049
interactions, 206f signal transduction and, 1443–1444, 1444f definition and history, 2047
in leukemic stem cells, 198 BCR-ABL1–negative cells, 1439, 1440 etiology and pathogenesis, 2047–2048
in life span of hematopoietic stem cells, BCR-ABL1–positive cells, 1439, 1440 laboratory features, 1839–1840, 1996
206 BCR-ABL1–positive thrombocythemia, 1449 molecular defects, 2048–2049, 2049f
in mitochondrial metabolism, 198 bcr-abl fusion protein, 230 platelet defects, 1839, 1867, 1868, 1877,
in myeloma, 1711 BCR-ABL kinase, 318 2048, 2359
p53 inhibition, 209 BCR-ABL peptide vaccine, 423 therapy, 1840
structure, 206 BCR-ABL–positive thrombocythemia, 1449 Berry cell. See Echinocytes
as therapeutic target, 1539 BCR-ABL tyrosine kinase inhibitors. See β-adrenergic blockers, 2295, 2296
Bcl-2 homologue protein, 2202 Tyrosine kinase inhibitors β-adrenergic receptors, 1059
BCL6 BCR breakpoints, 1442–1443, 1442f β-carotene, 899
in anaplastic large cell lymphoma, 1699 BCR rearrangement, 1447 β chemokines, 288t
in diffuse large B-cell lymphoma, 187, BCRs (B-cell receptors), 1151, 1528–1529 β-globin, 893
235t, 1625–1626, 1632 BEACOPP regimen, for Hodgkin lymphoma β-globin chains, 728
in follicular lymphoma, 1642, 1644 in advanced disease, 1613–1614 β-thalassemia and, 749–750
memory B cells and, 1172 adverse effects/complications, 1614, 1617 developmental switches in synthesis, 730
BCL7A, 166 clinical trials, 1614, 1615t vs. γ-globin chains, 760
BCL9, 1736 dose, route, and schedule, 1612t structure, 760–761, 760f
BCL11A, 484 in favorable limited-stage disease, 1613 variants, 733, 751

Kaushansky_index_p2393-2506.indd 2405 9/21/15 3:21 PM